(ST. LOUIS, November 8, 2012) — Mobius Therapeutics, LLC announced today the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedures Coding System (HCPCS) code for Mitosol® (mitomycin for solution) 0.2mg/vial, Kit for Ophthalmic Use.  Mitosol is used as an adjunct to ab externo glaucoma surgery.   The new J-code, J7315, becomes effective on January 1, 2013. 

"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed  Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC.  "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility. In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol’s quality manufacturing and convenience helps providers and patients with peace of mind.”

J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement.

#

About Mobius Therapeutics, LLC:

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions.  Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery.  The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.  Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.